The seventh batch of national procurement applications involving 200+ enterprises has been launched!

A variety of star items are listed

Injections account for nearly half

From the perspective of therapeutic areas, among the seventh batch of national harvests, anti-tumor and antibacterial drugs are the highlight
.
Anti-tumor drugs include irinotecan injection, lenvatinib mesylate capsules, afatinib maleate tablets, erlotinib hydrochloride tablets, sunitinib, temozolomide for injection, etc.
; antibacterial drugs include meropenem, Cefixime, Micafungin Injection, Tigecycline Injection
.

In addition, there are some big items in this round of national procurement, such as edaravone, oseltamivir,
etc.

Edaravone is one of the first batch of national key monitoring rational drug catalogues, and its national sales in 2019 are expected to be about 3 billion yuan
.
The data show that Edaravone injection is a brain protective agent (free radical scavenger), which is used to improve neurological symptoms, activities of daily living and dysfunction caused by acute cerebral infarction, and to inhibit amyotrophic lateral sclerosis caused by Progression of dysfunction
.
The drug was first developed by Tanabe Mitsubishi Pharmaceutical Co.
, Ltd.
under the trade name of RADICUT?, with a specification of 20ml: 30mg.
It was launched in Japan on June 1, 2001.
At present, the original formulation has not been launched in China
.
Domestic companies that have reviewed the drug include Shanghai Haini Pharmaceuticals of Yangzijiang Pharmaceutical Group, Guorui Pharmaceuticals of Sinopharm Group, Qilu Pharmaceuticals, Simcere Pharmaceuticals,
etc.

Oseltamivir, with sales of 6 billion in 2019, is currently the best-selling anti-influenza drug in China
.
A few days ago, oseltamivir was also listed in the list of the 11 provinces and regions in Guangdong’s alliance centralized procurement directory
.
Oseltamivir has been reviewed by domestic companies such as Kelun Pharmaceutical, CSPC Ouyi, Yichang Dongguang Changjiang Pharmaceutical,
etc.
The competitive landscape of oseltamivir has changed greatly.
Before, it was mainly sold by Sunshine, accounting for nearly 90% of the domestic market share, and Roche accounted for about 10%
.
For some "barefooters", successful selection may be able to seize a certain market share
.

It is worth noting that there are as many as 27 kinds of injections in the seventh batch of Guocai, accounting for 46.
5%, accounting for almost half of the country
.
Starting from the fourth batch of national mining, injections were included, and the proportion of injections in the fifth batch of national mining continued to increase, accounting for 48%
.
With the development of the consistency evaluation of injections, it is expected that more and more injections will be collected
.

Omeprazole injection is the product with the most over-evaluation companies.
A total of 24 generic drugs have passed the consistency evaluation, and the competition is fierce
.

Guorong Securities pointed out that from the perspective of the variety orientation of recent centralized procurement, the proportion of injections has been increasing.
Injections are the dosage form with the largest sales of pharmaceutical drugs in hospitals in China, with a market capacity of more than 500 billion yuan.
For pharmaceutical companies, the competitive landscape Still to be stabilized
.

In addition, the varieties with more than 10 over-rated companies include tenofovir alafenamide oral normal-release dosage form, clindamycin phosphate injection, cefixime oral normal-release dosage form, nifedipine sustained-release/controlled-release dosage form release form
.

03

not at a low price

Centralized procurement rules are becoming more and more mature

On February 11, 2022, the State Council Information Office held a regular briefing on State Council policies on deepening the reform of centralized procurement of drugs and high-value medical consumables
.
When answering a reporter's question, Chen Jinfu, deputy director of the National Medical Insurance Administration, said, "The rules of purchasing with quantity serve the system, requiring a link between quantity and price, ensuring quality, promoting innovation, stabilizing supply, and ensuring clinical use
.
At present, the country has formed around these aspects.
A series of institutional supporting policies have been formulated
.
Purchasing with quantity does not pursue the lowest price, and also firmly opposes running bidding.
The design of the rules is to achieve reasonable price adjustment and fair competition among enterprises.
.
.
"

Since the initial 4+7 pilot, the number of companies selected for centralized procurement has been gradually relaxed from one to several, and the relevant rules have been gradually improved and enriched
.
Special breeds also have specific regulatory requirements
.
In response to the phenomenon of supply interruption and insufficient supply of enterprises after the election, centralized procurement has further expanded the accessibility after the election to ensure supply.
At present, the rules are gradually being clarified
.
Regarding the upcoming seventh batch of national procurement rules, there is also news in the industry that there may be new changes, we will wait and see
.

In addition, on January 10, 2022, Premier Li Keqiang presided over an executive meeting of the State Council.
The meeting pointed out that it was decided to normalize and institutionalize the centralized procurement of drugs and high-value medical consumables.
Before the end of this year, the national and provincial centralized procurement of drugs will be Each province has a total of more than 350
.

At present, the national centralized procurement has involved 234 varieties, and the first six batches of centralized procurement of drugs have dropped by an average of 53%, and the amount involved accounts for 30% of the total annual drug procurement of public medical institutions
.
In addition to the 58 varieties reported in the seventh batch, the national centralized procurement involves a total of 292 varieties
.
According to the requirement of two batches a year and the supplement of provincial centralized procurement, the expansion of centralized drug procurement by the end of this year can basically meet expectations
.

Attachment: Scope of reporting for the seventh batch of domestically sourced drugs